Sorrento Therapeutics News and Activities

Sorrento Therapeutics is a company listed under the stock ticker SRNE (US).

View the org chart displaying its 14 main executives

Most searched biographies at Sorrento Therapeutics

• Henry Ji, Chairman, President and Chief Executive Officer
• Scott Schaus, Chief Technology Officer

Create your alert
to follow the executive moves at Sorrento Therapeutics.

Sorrento Therapeutics has 1,911 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• GNI has announced the acquisition of Ayumi Pharmaceutical  (posted on June 12 2026).
• Parabilis Medicines has just announced a $670 Million fundraising (posted on June 11 2026).
• Chiesi has acquired Kalvista Pharmaceuticals (posted on June 11 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Sorrento Therapeutics

• Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster | Sorrento Therapeutics
• Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc. | Sorrento Therapeutics
• News Releases | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors | Sorrento Therapeutics
• Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. | So
• Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes | Sorrento Therapeutics
• Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster | Sorrento Therapeutics
• Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans | Sorrento Therapeutics
• View more press releases Close

Social media about Sorrento Therapeutics

• Sorrento Therapeutics on Wikipedia, Google News & Yahoo Finance
• Sorrento Therapeutics on LinkedIn, X (Twitter) & YouTube